4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to -$1.01.
- 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) fell 2784.81% to -$1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.75, marking a year-over-year decrease of 3157.89%. This contributed to the annual value of -$2.98 for FY2024, which is 1558.7% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) is -$1.01, which was down 2784.81% from -$0.98 recorded in Q2 2025.
- 4D Molecular Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.24 during Q3 2023, with a 5-year trough of -$1.01 in Q3 2025.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.82 (2021), whereas its average is -$0.77.
- In the last 5 years, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 6962.03% in 2023 and then crashed by 22916.67% in 2024.
- 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.85 in 2021, then grew by 1.18% to -$0.84 in 2022, then grew by 8.33% to -$0.77 in 2023, then decreased by 19.58% to -$0.92 in 2024, then decreased by 9.69% to -$1.01 in 2025.
- Its EPS (Weighted Average and Diluted) was -$1.01 in Q3 2025, compared to -$0.98 in Q2 2025 and -$0.86 in Q1 2025.